AMARIN CORP PLC -ADR (AMRN) Stock Price, Forecast & Analysis
USA - NASDAQ:AMRN - US0231114044 - ADR
AMRN Key Statistics, Chart & Performance
The current stock price of AMRN is 15.71 USD. In the past month the price decreased by -13.82%. In the past year, price increased by 36.66%.
AMRN Latest News, Press Relases and Analysis
AMRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About AMRN
Company Profile
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Company Info
AMARIN CORP PLC -ADR
WeWork One Central Plaza Dame Street, Dublin 2
DUBLIN Dublin 2 IE
CEO: John F. Thero
Employees: 275
Phone: 35316699020
AMARIN CORP PLC -ADR / AMRN FAQ
What does AMRN do?
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
What is the stock price of AMARIN CORP PLC -ADR today?
The current stock price of AMRN is 15.71 USD. The price increased by 0.26% in the last trading session.
What is the dividend status of AMARIN CORP PLC -ADR?
AMRN does not pay a dividend.
What is the ChartMill rating of AMARIN CORP PLC -ADR stock?
AMRN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is AMARIN CORP PLC -ADR (AMRN) stock traded?
AMRN stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of AMRN stock?
AMARIN CORP PLC -ADR (AMRN) operates in the Health Care sector and the Biotechnology industry.
AMRN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is one of the better performing stocks in the market, outperforming 84.54% of all stocks.
AMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMRN. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability.
AMRN Financial Highlights
Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS increased by 65.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.14% | ||
| ROE | -18.9% | ||
| Debt/Equity | 0 |
AMRN Forecast & Estimates
8 analysts have analysed AMRN and the average price target is 10.88 USD. This implies a price decrease of -30.74% is expected in the next year compared to the current price of 15.71.
For the next year, analysts expect an EPS growth of 0.32% and a revenue growth 10.03% for AMRN